A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT06010329
Trial Phases:	Phase II	Protocol IDs:	TL-EGFR-2201 (primary) NCI-2023-10529
Eligibility:	18 - 75 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Teligene US
NCI Full Details:	http://clinicaltrials.gov/show/NCT06010329

Summary

The main objective of the study will be to evaluate the efficacy of sutetinib maleate
capsules in participants with locally advanced or metastatic non-small cell lung cancer
NSCLC (uncommon EGFR mutations only).

Objectives

Sutetinib is an investigational irreversible EGFR tyrosine kinase inhibitor. EGFR is a
gene that makes a protein that is involved in cell growth and cell survival. Mutated
(changed) forms of the EGFR gene and protein have been found in some types of cancer,
including non-small cell lung cancer. These changes may cause cancer cells to grow and
spread in the body. The purpose of this study is to explore how effective Sutetinib
maleate capsules are for the treatment of patients with locally advanced or metastatic
NSCLC with uncommon EGFR mutations.

Treatment Sites in Georgia

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.